Thrombolytic therapy with alteplase and recombinant prourokinase in massive pulmonary embolism
https://doi.org/10.30629/0023-2149-2021-99-3-177-186
Abstract
Analysis of clinical effi cacy and safety of alteplase and recombinant prourokinase in 82 patients with pulmonary embolism (PE) of high and intermediate high risk of death during the hospital observation period, whо were divided into two groups depending on the thrombolytic applied: the 1st group — recombinant prourokinase (40 people), the 2nd group — alteplase (42 people). The results of treatment, indicators of eff ectiveness and safety of thrombolytic therapy with alteplase and recombinant prourokinase were analyzed. The eff ectiveness and safety of thrombolytic therapy, evaluated clinically and instrumentally, did not diff er in the use of the drugs studied. However, at the time of development of PE from 5 to 14 days from the onset of the disease, for thrombolysis, it is preferable to use recombinant prourokinase, as it leads to a more signifi cant reduction in the volume of thrombotic masses than with the use of alteplase.
About the Authors
Yu. V Ovchinnikov
Military Medical Academy named after Kirov S.M. (Moscow Branch), Ministry of Defense of Russia
Russian Federation
Russian Federation
Ovchinnikov Yury Viktorovich - MD, PhD, DSc, prof., head
107392, Moscow
M. V. Zelenov
Central Military Clinical Hospital named after Mandryk P.V., Ministry of Defense of the Russian Federation
Russian Federation
Russian Federation
107014, Moscow
V. S. Polovinka
Military Medical Academy named after Kirov S.M. (Moscow Branch), Ministry of Defense of Russia
Russian Federation
Russian Federation
107392, Moscow
E. V. Kryukov
Military Medical Academy named after Kirov S.M., Ministry of Defense of the Russian Federation
Russian Federation
Russian Federation
194044, St. Petersburg
References
1. Bokarev I.N., Popova L.V. Venous thromboembolism and pulmonary embolism. 2013:512. (in Russian)]. ISBN: 978-5-9986-0129-3
2. Huisman M.V., Barco S., Cannegieter S.C. et al. Pulmonary embolism. Nat. Rev. Dis. Primers. 2018;4. [Electronic resource] URL: https://www.nature.com/articles/nrdp201828.
3. Martinez C., Cohen A.T., Bamber L., Rietbrock S. Epidemiology of fi rst and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb. Haemost. 2014;112(2):255–263.
4. Turetz M., Sideris A.T., Friedman O.A. et al. Epidemiology, pathophysiology, and natural history of pulmonary embolism. Semin. Intervent. Radiol. 2018;35(2):92–98.
5. Virk H.U.H., Chatterjee S., Sardar P. et al. Systemic thrombolysis for pulmonary embolism: evidence, patient selection, and protocols for management. Interv. Cardiol. Clin. 2018;7(1):71–80. DOI: 10.1016/j.iccl.2017.08.001
6. Halaby R., Giri J. Keep it simple? Half-dose systemic thrombolysis or catheter-directed thrombolysis for pulmonary embolism. Vasc. Med. 2019;5:1358863X18824653. DOI: 10.1177/1358863X18824653
7. Bokeria L.A., Zatechvatin I.I., Kirienko A.I. et al. Diagnostics and treatment of chronic venous disease: russian phlebological association clinical practice guidelines. Russian Phlebology journal. 2015;9(4/2):4–46. (in Russian)
8. Konstantinides S.V., Meyer G., Becattini С. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur. Heart J. [Electronic resource] URL: https://DOI.org/10.1093/eurheartj/ehz405.
9. D’Armini A.M. Diagnostic advances and opportunities in chronic thromboembolic pulmonary hypertension: review. Eur. Respir. Rev. 2015; 24:253–262.
10. Hao Q., Dong B.R., Yue J. et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst. Rev. 2015;9. [Electronic resource] URL:https://www.cochranelibrary.com/cdsr/DOI/10.1002/14651858.CD004437.pub4/full.
11. Konstantinides S.V., Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin. Respir. Crit. Care Med. 2017;38(1):56–65. DOI: 10.1055/s-0036-1597560
12. Miranda C.H. Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think. J. Bras. Pneumol. 2019;45(1):e20180297. DOI: 10.1590/1806-3713/e20180297
13. Kuzne tsechenko A.A., Tyurin V.P., Kitaev V.M., Linchak P.M. The signifi cance of CT angiography in the diagnosis and evaluation of the eff ectiveness of treatment of pulmonary embolism. Bulletin of the National Medical and Surgical Center named after N.I. Pirogov. 2008;1. (in Russian)]. [Electronic resource] URL: https://cyberleninka.ru/article/n/znachenie-kt-angiografii-v-diagnostike-i-otsenke-effektivnosti-lecheniya-tromboembolii-legochnoy-arterii (дата обращения: 17.05.2021).
14. Karaskov A.M., Karpenko A.A., Chernyavsky A.M. et al. Thrombolytic therapy of pulmonary artery thromboembolism with recombinant urokinase-type plasminogen activator Purolase. Medical technology. FS № 2011/104, Novosibirsk. 2010:1–16. (in Russian)
15. Sista A.K., Kuo W.T., Schiebler M. et al. Stratifi cation, imaging, and management of acute massive and submassive pulmonary embolism. Radiology. 2017;284(1):5–24.
16. Murphy E., Lababidi A., Reddy R. et al. The role of thrombolytic therapy for patients with a submassive pulmonary embolism. Cureus. 2018;10(6):e2814. DOI:10.7759/cureus.2814
17. Konstantinides S.V., Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin. Respir. Crit. Care Med. 2017;38(1):56–65. DOI: 10.1055/s-0036-1597560
18. Jiménez D., de Miguel-Díez J., Guijarro R., et al; RIETE Investigators. Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE Registry. J. Am. Coll. Cardiol. 2016;67(2):162–170. DOI: 10.1016/j.jacc.2015.10.060
19. Nikitina O.V., Mikhailov I.P., Kudryashova N.Y., Migunova E.V., Alekseyechkina O.A., Kungurtsev E.V., Udalova N.M., Khusainov S.Z., Kostyuchenko I.B. Thrombolytic and anticoagulant therapy for pulmonary embolism: an eff ect on pulmonary perfusion (part 2). Russian Sklifosovsky Journal Emergency Medical Care. 2018;7(2):134–143. (in Russian). DOI: 10.23934/2223-9022-2018-7-2-134-143
Review
For citations:
Ovchinnikov Yu.V., Zelenov M.V., Polovinka V.S., Kryukov E.V. Thrombolytic therapy with alteplase and recombinant prourokinase in massive pulmonary embolism. Clinical Medicine (Russian Journal). 2021;99(3):177-186. (In Russ.) https://doi.org/10.30629/0023-2149-2021-99-3-177-186
Views:
870
Email this article 